Xeris Biopharma Holdings annual return on equity
2021
2022
2023
Xeris Biopharma Holdings Return on Equity (ROE) Growth & History (XERS)
Xeris Biopharma Holdings's return on equity was −324.20% for fiscal 2023.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −324.20% | −189.38 pp |
| 2022 | 2022-12-31 | −134.83% | +55.46 pp |
| 2021 | 2021-12-31 | −190.28% | — |
Xeris Biopharma Holdings quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q3.23
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −1,898.14% | — |
| Q1 2026 | 2026-03-31 | 16.73% | — |
| Q4 2025 | 2025-12-31 | 172.76% | — |
| Q3 2023 | 2023-09-30 | −49.70% | −15.85 pp |
| Q4 2022 | 2022-12-31 | −25.80% | +83.70 pp |
| Q3 2022 | 2022-09-30 | −33.85% | +132.34 pp |
| Q2 2022 | 2022-06-30 | −30.73% | — |
| Q1 2022 | 2022-03-31 | −35.18% | — |
| Q4 2021 | 2021-12-31 | −109.50% | — |
| Q3 2021 | 2021-09-30 | −166.19% | — |
Xeris Biopharma Holdings return on equity trends
Between the periods ended 2021-12-31 and 2023-12-31, Xeris Biopharma Holdings's return on equity decreased from −190.28% to −324.20%, a change of −133.92 percentage points. The latest reported quarter, Q2 2026, shows −1,898.14%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xeris Biopharma Holdings source filings ↗